References in periodicals archive ?
The editor has organized the contributions that make up the main body of the text in three alphabetical volumes devoted to abarelix, barium enema, cancer biology, dacarbazine, endocrine system tumors, xerostomia, zolpidem, and a wide variety of other related subjects in between.
Some examples of the 25 designated medications are alosetron (Lotronex), which is used to treat irritable bowel syndrome but can cause serious gastrointestinal side effects; ambrisentan (Letairis), which is used to treat pulmonary arterial hypertension but can cause liver damage and birth defects; and abarelix (Plenaxis), which is used to treat prostate cancer but can cause a serious allergic reaction.
Contemporary therapies have varying mechanisms of action, including combined androgen blockage (gonadotrophin-releasing hormone agonist [eg, goserelin and leuprolide] combined with an androgen receptor antagonist [eg, flutamide, bicalutamide, and nilutamide]), gonadotrophin-releasing hormone antagonists (eg, abarelix), and 5[alpha]-reductase inhibitors (eg, finasteride and dutasteride).
In the first study, 177 men were treated with abarelix or with goserelin plus bicalutamide.
In the first study, 177 men were treated with abarelix, or goserelin plus bicalutamide.
This degree of prolongation was seen in 6% of the men treated with leuprolide alone, and in 2%-4% of those treated with abarelix. None treated with leuprolide plus bicalutamide had a prolongation of more than 60 msec.
In 2002 analysts expect the launch of SD/01, for breast cancer, and Abarelix, for prostate cancer.
Amgen's four late-stage development programs, NESP, IL-1ra, abarelix and SD/01 continued to progress during the first quarter, and the company is planning to launch these products in 2001 and 2002.
Targeting FSH in androgen-independent prostate cancer: Abarelix for prostate cancer progressing after orchiectomy.
A little further out are SD01, for breast cancer, and Abarelix, for prostate cancer.
In the questionnaire ADT included agents: gonadotropin-releasing hormone antagonists (GnRH) agonists (e.g., leuprolide, goserelin), GnRH antagonists (e.g., abarelix), oral androgen ablation agents (e.g., ketoconazole), oral non-steroidal antiandrogens/androgen receptor antagonists (e.g.